CStone Pharmaceuticals today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental new drug application (sNDA) of selective RET inhibitor GAVRETO® (pralsetinib) for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC). The approval expanded the labeled indications of GAVRETO in China to include adult…
eTurboNews artikujt janë vetëm për abonentët. Abonimi është FALAS.
Abonentët identifikohen këtu Klikoni këtu për t'u abonuar FALAS
Abonentët identifikohen këtu Klikoni këtu për t'u abonuar FALAS
ÇFARË TË HIQET KY ARTIKU:
- The approval expanded the labeled indications of GAVRETO in China to include adult….
- CStone Pharmaceuticals today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental new drug application (sNDA) of selective RET inhibitor GAVRETO® (pralsetinib) for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC).
- eTurboNews artikujt janë vetëm për abonentët.
